JPH08778B2 - アルツハイマー病治療薬 - Google Patents
アルツハイマー病治療薬Info
- Publication number
- JPH08778B2 JPH08778B2 JP62007684A JP768487A JPH08778B2 JP H08778 B2 JPH08778 B2 JP H08778B2 JP 62007684 A JP62007684 A JP 62007684A JP 768487 A JP768487 A JP 768487A JP H08778 B2 JPH08778 B2 JP H08778B2
- Authority
- JP
- Japan
- Prior art keywords
- galantamine
- alzheimer
- disease
- administered
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims description 3
- 229940079593 drug Drugs 0.000 title description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims abstract description 57
- 229960003980 galantamine Drugs 0.000 claims abstract description 28
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 13
- 239000002775 capsule Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 125000005037 alkyl phenyl group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002024 galantamine hydrobromide Drugs 0.000 description 2
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- -1 methoxy, ethoxy, acetyloxy, methoxy group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical class [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/819,141 US4663318A (en) | 1986-01-15 | 1986-01-15 | Method of treating Alzheimer's disease |
| US819141 | 1986-01-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62215527A JPS62215527A (ja) | 1987-09-22 |
| JPH08778B2 true JPH08778B2 (ja) | 1996-01-10 |
Family
ID=25227312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62007684A Expired - Fee Related JPH08778B2 (ja) | 1986-01-15 | 1987-01-16 | アルツハイマー病治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4663318A (en, 2012) |
| EP (1) | EP0236684B1 (en, 2012) |
| JP (1) | JPH08778B2 (en, 2012) |
| AT (1) | ATE76294T1 (en, 2012) |
| AU (1) | AU593051B2 (en, 2012) |
| DE (3) | DE10199020I2 (en, 2012) |
| ES (1) | ES2000428T3 (en, 2012) |
| GR (2) | GR880300077T1 (en, 2012) |
| LU (1) | LU90710I2 (en, 2012) |
| NL (1) | NL300140I2 (en, 2012) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| EP0363415B1 (en) * | 1987-05-04 | 2008-10-15 | Davis, Bonnie | Compounds for the treatment of alzheimer's disease |
| IT1222395B (it) * | 1987-07-30 | 1990-09-05 | Pierrel Spa | Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare |
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| DE4010079A1 (de) * | 1990-03-29 | 1991-10-02 | Lohmann Therapie Syst Lts | Pharmazeutische formulierung zur behandlung des alkoholismus |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| EP0584185B1 (en) * | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| US5177070A (en) * | 1991-11-15 | 1993-01-05 | Ciba-Geigy Corporation | Method of treating physiologic male erectile impotence |
| DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
| DE4301782C1 (de) * | 1993-01-23 | 1994-08-25 | Lohmann Therapie Syst Lts | Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit |
| US6316439B1 (en) * | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| DK0787115T3 (da) * | 1994-10-21 | 2000-05-08 | Sanochemia Pharmazeutika Ag | Fremgangsmåde til fremstilling af 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinderivater |
| US6407229B1 (en) | 1994-10-21 | 2002-06-18 | Sanochemia Pharmazeutika Ag | Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9514821D0 (en) * | 1995-07-19 | 1995-09-20 | Sod Conseils Rech Applic | Galanthamine derivatives |
| AT402691B (de) * | 1996-01-26 | 1997-07-25 | Sanochemia Ltd | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
| US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| AU2004242546B2 (en) * | 1998-11-23 | 2008-05-15 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| SI1140105T1 (en) * | 1998-12-24 | 2004-04-30 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
| US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
| ES2243241T3 (es) * | 2000-01-28 | 2005-12-01 | Tricia Grose | Suplemento herbario para el deterioro cognitivo relacionado con la perdida de estrogenos. |
| US6426097B2 (en) | 2000-01-28 | 2002-07-30 | Herbaceuticals Inc. | Herbal supplement for cognitive related impairment due to estrogen loss |
| NZ516302A (en) | 2000-03-31 | 2004-02-27 | Sanochemia Pharmazeutika Ag | Novel derivatives and analogues of galanthamin |
| CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| CA2310990A1 (en) | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
| EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
| JP4721386B2 (ja) * | 2001-07-10 | 2011-07-13 | 第一三共株式会社 | 新規ガランタミン類縁体 |
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| DK1514542T3 (da) | 2002-06-14 | 2012-04-10 | Toyama Chemical Co Ltd | Medicinsk sammensætning omfattende Tacrin eller Donepezil til forbedring af hjernefunktionen |
| US20040067934A1 (en) * | 2002-10-03 | 2004-04-08 | Parys Wim Louis Julien | Use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| WO2004037234A2 (en) * | 2002-10-24 | 2004-05-06 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| US20040097484A1 (en) * | 2002-11-14 | 2004-05-20 | Marc Cantillion | Once a day galantamine pharmaceutical compositions and methods of use |
| WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
| US20050004104A1 (en) * | 2003-05-30 | 2005-01-06 | Cali Brian M. | Methods for the protection of memory and cognition |
| JP2007528857A (ja) * | 2003-07-11 | 2007-10-18 | ミリアド ジェネティクス， インコーポレイテッド | アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態 |
| US20050048543A1 (en) * | 2003-07-11 | 2005-03-03 | Jeroen Aerssens | CHRNA2 genetic markers associated with galantamine response |
| BRPI0412919A (pt) * | 2003-07-25 | 2006-09-26 | Hoffmann La Roche | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos |
| WO2005042762A2 (en) * | 2003-10-28 | 2005-05-12 | Genaissance Pharmaceuticals, Inc. | Lrpap1 genetic markers associated with galantamine response |
| BG65658B1 (bg) * | 2003-11-13 | 2009-05-29 | "Софарма" Ад | Комбиниран лекарствен продукт на основата на галантамин |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US7250258B2 (en) * | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
| CA2552114A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| CA2551946A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galantamine |
| CN1921844A (zh) * | 2004-02-19 | 2007-02-28 | 诺瓦提斯公司 | 胆碱酯酶抑制剂治疗血管性抑郁症的用途 |
| WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
| CN1946906A (zh) * | 2004-04-29 | 2007-04-11 | 吉斯通护岸系统股份有限公司 | 用于墙、护墙和类似物的饰面 |
| US20050267076A1 (en) * | 2004-05-14 | 2005-12-01 | Johns Hopkins University | Method for improving cognitive function |
| WO2006004201A1 (ja) * | 2004-07-01 | 2006-01-12 | Eisai R & D Management Co., Ltd. | 神経再生促進剤 |
| WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| AU2005308575A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia |
| AU2005322611A1 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or NMDA receptor antagonists for the treatment of Alzheimer's disease |
| AU2006244297A1 (en) * | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of CNS disorders |
| US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
| US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
| EA200800360A1 (ru) * | 2005-07-22 | 2008-06-30 | Мириад Дженетикс, Инк. | Формуляции с высоким содержанием лекарства и дозированные формы |
| US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
| BRPI0718437A2 (pt) | 2006-10-27 | 2013-11-19 | Medivation Neurology Inc | Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil |
| US20110201597A1 (en) | 2008-03-27 | 2011-08-18 | Chase Thomas N | Method and composition for treating alzheimer-type dementia |
| WO2009120277A1 (en) | 2008-03-27 | 2009-10-01 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| EP2478099B1 (en) | 2009-09-18 | 2019-06-05 | Chase Pharmaceuticals Corporation | Combination for treating alzheimer-type dementia |
| CA2781826A1 (en) | 2009-11-26 | 2011-06-03 | Usv Limited | Controlled release pharmaceutical compositions of galantamine |
| CA2789014C (en) | 2010-02-09 | 2019-01-15 | Michela Gallagher | Methods and compositions for improving cognitive function |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| FR2962335B1 (fr) | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
| BR122016020434A2 (pt) | 2012-09-05 | 2019-08-27 | Chase Pharmaceuticals Corp | combinação farmacêutica e uso de um nspacha, de um achei e de um naaea |
| HK1215170A1 (zh) | 2012-11-14 | 2016-08-19 | The Johns Hopkins University | 治療精神分裂症的方法和組合物 |
| BG66818B1 (bg) | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| EP3033082B1 (en) | 2013-08-16 | 2021-06-16 | Universiteit Maastricht | Treatment of cognitive impairment with pde4 inhibitor |
| CN112843005B (zh) | 2015-05-22 | 2023-02-21 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
-
1986
- 1986-01-15 US US06/819,141 patent/US4663318A/en not_active Expired - Lifetime
-
1987
- 1987-01-15 ES ES198787100461T patent/ES2000428T3/es not_active Expired - Lifetime
- 1987-01-15 EP EP87100461A patent/EP0236684B1/en not_active Expired - Lifetime
- 1987-01-15 DE DE2001199020 patent/DE10199020I2/de active Active
- 1987-01-15 AT AT87100461T patent/ATE76294T1/de not_active IP Right Cessation
- 1987-01-15 DE DE198787100461T patent/DE236684T1/de active Pending
- 1987-01-15 AU AU67609/87A patent/AU593051B2/en not_active Expired
- 1987-01-15 DE DE8787100461T patent/DE3779149D1/de not_active Expired - Lifetime
- 1987-01-16 JP JP62007684A patent/JPH08778B2/ja not_active Expired - Fee Related
-
1988
- 1988-10-21 GR GR88300077T patent/GR880300077T1/el unknown
-
1992
- 1992-08-20 GR GR920400780T patent/GR3005447T3/el unknown
-
2001
- 2001-01-03 LU LU90710C patent/LU90710I2/fr unknown
-
2003
- 2003-12-04 NL NL300140C patent/NL300140I2/nl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE10199020I1 (de) | 2001-05-23 |
| EP0236684B1 (en) | 1992-05-20 |
| ES2000428T3 (es) | 1993-10-01 |
| GR880300077T1 (en) | 1988-10-21 |
| GR3005447T3 (en, 2012) | 1993-05-24 |
| DE3779149D1 (de) | 1992-06-25 |
| ATE76294T1 (de) | 1992-06-15 |
| DE10199020I2 (de) | 2004-05-06 |
| LU90710I2 (fr) | 2001-03-05 |
| EP0236684A2 (en) | 1987-09-16 |
| JPS62215527A (ja) | 1987-09-22 |
| DE236684T1 (de) | 1988-04-28 |
| ES2000428A4 (es) | 1988-03-01 |
| AU6760987A (en) | 1987-07-16 |
| US4663318A (en) | 1987-05-05 |
| ES2000428T9 (es) | 2013-08-14 |
| NL300140I2 (nl) | 2004-04-01 |
| EP0236684A3 (en) | 1988-12-14 |
| AU593051B2 (en) | 1990-02-01 |
| NL300140I1 (nl) | 2004-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH08778B2 (ja) | アルツハイマー病治療薬 | |
| JP4212149B2 (ja) | 医薬 | |
| JP3221611B2 (ja) | 物質乱用障害の治療用医薬組成物 | |
| RU2126254C1 (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, и способ лечения | |
| JPH02326B2 (en, 2012) | ||
| CA2258696A1 (en) | A method of treating liver disease and like indications with vasodilating agents | |
| EP1218010A2 (en) | 1,4-benzothiazepines to treat obesity related disorders | |
| US5496823A (en) | Pharmaceutical composition for increasing bladder capacity | |
| US5516773A (en) | Agent for treating high blood pressure and cardiac insufficiency | |
| US7354949B2 (en) | Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia | |
| RU2197245C2 (ru) | Пиридил- и пиримидил-пиперазины в лечении болезней, вызываемых злоупотреблением лекарственными и/или наркотическими веществами | |
| US4307097A (en) | Method of reducing increased intracranial pressure | |
| US7276532B2 (en) | Remedies for vesical hyperactivity | |
| US7074961B2 (en) | Antidepressants and their analogues as long-acting local anesthetics and analgesics | |
| US20040106671A1 (en) | Remedies for vesical hyperesthesia | |
| US3743746A (en) | Process of treating peptic ulcer with a non-anticholinergic agent | |
| JP2004535457A (ja) | ピリダジノン誘導体の新しい用途 | |
| KR920003580B1 (ko) | 동맥경화증 예방 및 치료제 | |
| CA1263843A (en) | Treatment of sleep disorders | |
| US3867532A (en) | Diazabicyclodecanes as anti-ulcer agents | |
| AU738047B2 (en) | Use of NK-1 receptor antagonists for treating mania | |
| JP2773432B2 (ja) | 抗うつ剤 | |
| EP0429245A2 (en) | A therapeutic agent for central nervous diseases | |
| JPH07138226A (ja) | 新規な血行促進のために使用する医薬 | |
| MXPA06008180A (es) | Metodo para tratar disfuncion erectil. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |